Drugs / AL-034
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03285620 | Sep 2017 → Nov 2018 | hepatitis B virus infection | Alios Biopharma Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AL-034 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03285620 ↗ |
| Route | Oral | “Participants will receive single oral dose of AL-034 under fed or fasted conditions in part 1 and part 2” NCT03285620 ↗ |